Transcept Pharmaceuticals to present at two upcoming investor conferences
Transcept Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced Transcept management is scheduled to present at two upcoming investor conferences.
Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen ® and Synacthen Depot in the US from Novartis Pharma AG and Novartis AG. Subject to certain closing conditions, Questcor has also acquired rights to Synacthen ® and Synacthen Depot ® in certain countries outside the US Available in more than forty countries for multiple indications, Synacthen is a synthetic 24 amino acid melanocortin receptor agonist.